share_log

Canaccord Genuity Maintains Hold on Biomarin Pharmaceutical, Lowers Price Target to $89

Benzinga ·  Apr 26 08:48

Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Hold and lowers the price target from $91 to $89.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment